190 related articles for article (PubMed ID: 24149834)
1. A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.
Stratikos E; Chroni A
Clin Exp Nephrol; 2014 Apr; 18(2):225-9. PubMed ID: 24149834
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.
Matsunaga A; Saito T
Clin Exp Nephrol; 2014 Apr; 18(2):220-4. PubMed ID: 24570178
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E-related glomerular disorders.
Saito T; Matsunaga A; Fukunaga M; Nagahama K; Hara S; Muso E
Kidney Int; 2020 Feb; 97(2):279-288. PubMed ID: 31874799
[TBL] [Abstract][Full Text] [Related]
4. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy.
Saito T; Ishigaki Y; Oikawa S; Yamamoto TT
Trends Cardiovasc Med; 2002 Feb; 12(2):67-70. PubMed ID: 11852253
[TBL] [Abstract][Full Text] [Related]
5. A novel apolipoprotein E mutation caused by a five amino acid deletion in a Chinese family with lipoprotein glomerulopathy: a case report.
Xie W; Xie Y; Lin Z; Xu X; Zhang Y
Diagn Pathol; 2019 May; 14(1):41. PubMed ID: 31092271
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America.
da Silveira-Neto JN; de Oliveira Ahn GJ; de Menezes Neves PDM; Baptista VAF; de Almeida Araújo S; Wanderley DC; Watanabe A; Watanabe EH; Murai NM; Bertollo EMG; Vieira-Neto OM; Dantas M; de Antônio SR; Costa RS; Baptista MASF; Moysés-Neto M; Onuchic LF
Diagn Pathol; 2021 Jul; 16(1):65. PubMed ID: 34311745
[TBL] [Abstract][Full Text] [Related]
7. Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy.
Georgiadou D; Stamatakis K; Efthimiadou EK; Kordas G; Gantz D; Chroni A; Stratikos E
J Lipid Res; 2013 Jan; 54(1):164-76. PubMed ID: 23110818
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Li LS
J Nephrol; 2008; 21(1):110-7. PubMed ID: 18264944
[TBL] [Abstract][Full Text] [Related]
9. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy.
Bomback AS; Song H; D'Agati VD; Cohen SD; Neal A; Appel GB; Rovin BH
Nephrol Dial Transplant; 2010 Oct; 25(10):3442-6. PubMed ID: 20624773
[TBL] [Abstract][Full Text] [Related]
10. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.
Matsunaga A; Sasaki J; Komatsu T; Kanatsu K; Tsuji E; Moriyama K; Koga T; Arakawa K; Oikawa S; Saito T; Kita T; Doi T
Kidney Int; 1999 Aug; 56(2):421-7. PubMed ID: 10432380
[TBL] [Abstract][Full Text] [Related]
11. Topics in lipoprotein glomerulopathy: an overview.
Saito T; Matsunaga A; Ito K; Nakashima H
Clin Exp Nephrol; 2014 Apr; 18(2):214-7. PubMed ID: 24149835
[TBL] [Abstract][Full Text] [Related]
12. The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T＞C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy.
Wu H; Yang Y; Hu Z
J Atheroscler Thromb; 2018 Aug; 25(8):733-740. PubMed ID: 29398675
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein glomerulopathy in China.
Chen Y
Clin Exp Nephrol; 2014 Apr; 18(2):218-9. PubMed ID: 24165683
[TBL] [Abstract][Full Text] [Related]
14. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Zhou H; Li LS
Chin Med J (Engl); 2005 Apr; 118(7):555-60. PubMed ID: 15820086
[TBL] [Abstract][Full Text] [Related]
15. Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy.
Katsarou M; Stratikos E; Chroni A
J Lipid Res; 2018 Dec; 59(12):2339-2348. PubMed ID: 30309894
[TBL] [Abstract][Full Text] [Related]
16. Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations.
Yang M; Weng Q; Pan X; Hussain HMJ; Yu S; Xu J; Yu X; Liu Y; Jin Y; Zhang C; Li X; Ren H; Chen N; Xie J
Mol Genet Genomic Med; 2020 Aug; 8(8):e1281. PubMed ID: 32441489
[TBL] [Abstract][Full Text] [Related]
17. [A 3-amino acid deletion of apolipoprotein E found in 3 Chinese lipoprotein glomerulopathy patients].
Chen YQ; Zhang H; Zhu SL; Zou WZ; Wang M; Liu ZS; Wang HY
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):774-7. PubMed ID: 12899757
[TBL] [Abstract][Full Text] [Related]
18. A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy.
Toyota K; Hashimoto T; Ogino D; Matsunaga A; Ito M; Masakane I; Degawa N; Sato H; Shirai S; Umetsu K; Tamiya G; Saito T; Hayasaka K
J Hum Genet; 2013 May; 58(5):254-8. PubMed ID: 23407349
[TBL] [Abstract][Full Text] [Related]
19. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.
Luo B; Huang F; Liu Q; Li X; Chen W; Zhou SF; Yu X
Am J Nephrol; 2008; 28(2):347-53. PubMed ID: 18046082
[TBL] [Abstract][Full Text] [Related]
20. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.
Ishigaki Y; Oikawa S; Suzuki T; Usui S; Magoori K; Kim DH; Suzuki H; Sasaki J; Sasano H; Okazaki M; Toyota T; Saito T; Yamamoto TT
J Biol Chem; 2000 Oct; 275(40):31269-73. PubMed ID: 10903326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
